{"title":"[黑色素瘤的辅助和新辅助治疗]。","authors":"Dirk Debus, Axel Hauschild, Erwin S Schultz","doi":"10.1055/a-2453-8887","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"150 10","pages":"555-561"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Adjuvant and neoadjuvant therapy of melanoma].\",\"authors\":\"Dirk Debus, Axel Hauschild, Erwin S Schultz\",\"doi\":\"10.1055/a-2453-8887\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.</p>\",\"PeriodicalId\":93975,\"journal\":{\"name\":\"Deutsche medizinische Wochenschrift (1946)\",\"volume\":\"150 10\",\"pages\":\"555-561\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deutsche medizinische Wochenschrift (1946)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2453-8887\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche medizinische Wochenschrift (1946)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2453-8887","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
